Aktuellt
SENASTE
FluoGuide announced that it has determined to develop FG001 for non-metastatic lung cancer, the second indication after high-grade glioma, and that it will initiate a phase 2 trial around the start of 2022, with enrollment of up to 24 patients planned and top-line results expected by YE-2022. Lung cancer is a far larger indication than glioma and it is good to see management continuing to make rapid progress with its pipeline. Small positive.
LÄS MER
